Strs Ohio Takes Position in Harmony Biosciences Holdings, Inc. $HRMY

Strs Ohio acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 17,700 shares of the company’s stock, valued at approximately $587,000.

Other large investors also recently made changes to their positions in the company. Aurora Investment Counsel lifted its holdings in Harmony Biosciences by 0.6% during the 1st quarter. Aurora Investment Counsel now owns 61,667 shares of the company’s stock valued at $2,047,000 after purchasing an additional 374 shares during the last quarter. Rhumbline Advisers lifted its holdings in Harmony Biosciences by 0.4% during the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company’s stock valued at $3,620,000 after purchasing an additional 485 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Harmony Biosciences by 1.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 62,331 shares of the company’s stock valued at $2,145,000 after purchasing an additional 678 shares during the last quarter. CWM LLC lifted its holdings in Harmony Biosciences by 34.8% during the 1st quarter. CWM LLC now owns 2,704 shares of the company’s stock valued at $90,000 after purchasing an additional 698 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in Harmony Biosciences by 6.4% during the 1st quarter. Arizona State Retirement System now owns 12,261 shares of the company’s stock valued at $407,000 after purchasing an additional 737 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HRMY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $55.00 price target (up previously from $54.00) on shares of Harmony Biosciences in a report on Thursday, July 10th. Truist Financial started coverage on Harmony Biosciences in a report on Monday, July 21st. They set a “buy” rating and a $48.00 target price for the company. Oppenheimer started coverage on Harmony Biosciences in a report on Monday, June 2nd. They set an “outperform” rating and a $61.00 target price for the company. The Goldman Sachs Group started coverage on Harmony Biosciences in a report on Thursday, July 10th. They set a “neutral” rating and a $33.00 target price for the company. Finally, Wall Street Zen raised Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Harmony Biosciences has an average rating of “Buy” and an average target price of $51.00.

Harmony Biosciences Price Performance

Shares of HRMY opened at $32.54 on Friday. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84. The business’s 50 day moving average price is $35.53 and its two-hundred day moving average price is $33.53. The firm has a market cap of $1.87 billion, a PE ratio of 10.50, a price-to-earnings-growth ratio of 0.38 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The firm had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. During the same period in the previous year, the company earned $1.05 earnings per share. Harmony Biosciences’s revenue for the quarter was up 16.0% compared to the same quarter last year. Harmony Biosciences has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.